Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020

Article  PubMed  PubMed Central  Google Scholar 

Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [published correction appears in Eur J Endocrinol 155(2):385]. Eur J Endocrinol 154(6):787–803. https://doi.org/10.1530/eje.1.02158

Article  CAS  PubMed  Google Scholar 

Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [published correction appears in Am J Med 98(2):215]. Am J Med 97(5):418–428. https://doi.org/10.1016/0002-9343(94)90321-2

Article  CAS  PubMed  Google Scholar 

Goldsmith SJ (2011) To ablate or not to ablate: issues and evidence involved in 131I ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma. Semin Nucl Med 41(2):96–104. https://doi.org/10.1053/j.semnuclmed.2010.11.002

Article  PubMed  Google Scholar 

Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229–1242. https://doi.org/10.1089/thy.2006.16.1229

Article  PubMed  Google Scholar 

Durante C, Haddy N, Baudin E et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8):2892–2899. https://doi.org/10.1210/jc.2005-2838

Article  CAS  PubMed  Google Scholar 

Mandel SJ, Mandel L (2003) Radioactive iodine and the salivary glands. Thyroid 13(3):265–271. https://doi.org/10.1089/105072503321582060

Article  CAS  PubMed  Google Scholar 

Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA (2002) Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87(12):5817–5820. https://doi.org/10.1210/jc.2002-020210

Article  CAS  PubMed  Google Scholar 

Hyer SL, Newbold K, Harmer CL (2010) Early and late toxicity of radioiodine therapy: detection and management. Endocr Pract 16(6):1064–1070. https://doi.org/10.4158/EP10170.RA

Article  PubMed  Google Scholar 

Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY (2012) Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 151(6):844–850. https://doi.org/10.1016/j.surg.2011.12.019

Article  PubMed  Google Scholar 

Haynie TP, Beierwaltes WH (1963) Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med 4:85–91

CAS  PubMed  Google Scholar 

Keldsen N, Mortensen BT, Hansen HS (1990) Haematological effects from radioiodine treatment of thyroid carcinoma. Acta Oncol 29(8):1035–1039. https://doi.org/10.3109/02841869009091796

Article  CAS  PubMed  Google Scholar 

Petrich T, Widjaja A, Musholt TJ et al (2001) Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28(2):203–208. https://doi.org/10.1007/s002590000420

Article  CAS  PubMed  Google Scholar 

Singer PA, Cooper DS, Daniels GH et al (1996) Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 156(19):2165–2172

Article  CAS  PubMed  Google Scholar 

Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35(10):1941–1959. https://doi.org/10.1007/s00259-008-0883-1

Article  CAS  PubMed  Google Scholar 

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [published correction appears in Thyroid 20(8):942. Hauger, Bryan R [corrected to Haugen, Bryan R]] [published correction appears in Thyroid 20(6):674–5]. Thyroid 19(11):1167–1214. https://doi.org/10.1089/thy.2009.0110

Perrier ND, Brierley JD, Tuttle RM (2018) Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68(1):55–63. https://doi.org/10.3322/caac.21439

National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE v5.0) Washington, DC: National Cancer Institute, Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed October 10, 2019

Molinaro E, Leboeuf R, Shue B et al (2009) Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid 19(10):1035–1041. https://doi.org/10.1089/thy.2008.0430

Article  PubMed  Google Scholar 

Padovani RP, Tuttle RM, Grewal R, Larson SM, Boucai L (2014) Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer. Endocr Pract 20(3):213–220. https://doi.org/10.4158/EP13172.OR

Article  PubMed  Google Scholar 

Prinsen HT, Klein Hesselink EN, Brouwers AH et al (2015) Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab 100(10):3911–3917. https://doi.org/10.1210/jc.2015-2124

Article  CAS  PubMed  Google Scholar 

Sönmez B, Bektaş Ö, Erkut N, Sönmez M (2021) Assessment of Long-Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine. Turk J Haematol 38(4):306–313. https://doi.org/10.4274/tjh.galenos.2021.2021.0092

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu T, Meng Z, Zhang G et al (2016) Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer. Medicine (Baltimore) 95(35):e4451. https://doi.org/10.1097/MD.0000000000004451

Yi W, Kim BH, Kim M et al (2020) Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment. Endocr J 67(12):1193–1198. https://doi.org/10.1507/endocrj.EJ20-0242

Article  CAS  PubMed  Google Scholar 

Yamashita K, Morimoto S, Kimura S et al (2021) Transient Leukopenia After Radioactive Iodine Treatment in Patients With Graves' Disease: A Retrospective Cohort Study. J Endocr Soc 5(5):bvab039. https://doi.org/10.1210/jendso/bvab039

Duskin-Bitan H, Leibner A, Amitai O et al (2019) Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data. Thyroid 29(5):683–691. https://doi.org/10.1089/thy.2018.0423

Article  CAS  PubMed  Google Scholar 

Dong P, Wang L, Huang R, Li L (2020) Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy. Medicine (Baltimore) 99(31):e21398. https://doi.org/10.1097/MD.0000000000021398

Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE (2018) Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 15(11):e1002685. https://doi.org/10.1371/journal.pmed.1002685

Larson SM, Raubitschek A, Reynolds JC et al (1989) Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man. Int J Rad Appl Instrum B 16(2):153–158. https://doi.org/10.1016/0883-2897(89)90188-8

Article  CAS  PubMed  Google Scholar 

Monzen S, Mariya Y, Wojcik A et al (2015) Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients. Mol Clin Oncol 3(3):692–698. https://doi.org/10.3892/mco.2015.499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dainiak N (2002) Hematologic consequences of exposure to ionizing radiation. Exp Hematol 30(6):513–528. https://doi.org/10.1016/s0301-472x(02)00802-0

Article  CAS  PubMed  Google Scholar 

Dong P, Qu Y, Yang L, Xiao L, Huang R, Li L (2021) Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial. Clin Endocrinol (Oxf) 95(5):782–789. https://doi.org/10.1111/cen.14563

Article  CAS  PubMed  Google Scholar 

Hay ID, Kaggal S, Thompson GB (2022) Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?. Eur Thyroid J 11(4):e220084. https://doi.org/10.1530/ETJ-22-0084